Weight gain associated with taking psychotropic medication: An integrative review
- 18 February 2011
- journal article
- review article
- Published by Wiley in International Journal of Mental Health Nursing
- Vol. 20 (3) , 202-222
Abstract
People with serious mental illness have higher morbidity and mortality rates than general populations, and overweight/obesity-related conditions are prevalent. Psychotropic medications are a primary factor in significant weight gain. Adolescents and young adults, particularly those with first-episode psychoses taking atypical antipsychotics, are susceptible to weight gain. This paper reports findings from an integrative review of research investigating the impact and treatment of psychotropic-induced weight gain. Four databases were searched, yielding 522 papers. From these and hand-searched papers, 36 research reports were systematically classified and analysed. The review revealed people experiencing psychotropic-induced weight gain perceive it as distressing. It impacts on quality of life and contributes to treatment non-adherence. Weight management and prevention strategies have primarily targeted adults with existing/chronic illness rather than those with first-episode psychoses and/or drug naiveté. Single and multimodal interventions to prevent or manage weight gain produced comparable, modest results. This review highlights that the effectiveness of weight management interventions is not fully known, and there is a lack of information regarding weight gain prevention for young people taking psychotropics. Future research directions include exploring the needs of young people regarding psychotropic-related weight gain and long-term, follow-up studies of lifestyle interventions to prevent psychotropic-related weight gain.Keywords
This publication has 81 references indexed in Scilit:
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- A Naturalistic Multicenter Trial of a 12-Week Weight Management Program for Overweight and Obese Patients With Schizophrenia or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2008
- Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic DisordersCNS Drugs, 2008
- Distress with Medication Side Effects among Persons with Severe Mental IllnessAdministration and Policy in Mental Health and Mental Health Services Research, 2007
- Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysisSchizophrenia Research, 2007
- Psychotropic Medication Utilization in a Child and Adolescent Mental Health ServiceJournal of Child and Adolescent Psychopharmacology, 2006
- Weight Management Program for Treatment-Emergent Weight Gain in Olanzapine-Treated Patients With Schizophrenia or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2006
- First-Episode SchizophreniaDrugs, 2005
- The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophreniaLife Sciences, 2004